APA

Wåhlander K., Eriksson H., Lundström T., Billing Clason S., Wall U., Nyström P., Wessman P. & Schulman S. (20060503). Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism. : British journal of haematology.

Chicago

Wåhlander Karin, Eriksson Henry, Lundström Torbjörn, Billing Clason Solveig, Wall Ulrika, Nyström Per, Wessman Peter and Schulman Sam. 20060503. Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism. : British journal of haematology.

Harvard

Wåhlander K., Eriksson H., Lundström T., Billing Clason S., Wall U., Nyström P., Wessman P. and Schulman S. (20060503). Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism. : British journal of haematology.

MLA

Wåhlander Karin, Eriksson Henry, Lundström Torbjörn, Billing Clason Solveig, Wall Ulrika, Nyström Per, Wessman Peter and Schulman Sam. Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism. : British journal of haematology. 20060503.